Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sheel BiotechNSE:SHEEL -3.30%19 ROC (Joel Greenblatt) % is 14.29% as of Mar. 2026, which is at its 10-year median of 14.29. GuruFocus rates NSE:SHEEL with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,983 Consumer Packaged Goods companies, Sheel Biotech ranks better than 54.72% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sheel Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.29%.
The historical rank and industry rank for Sheel Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:SHEEL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.77 Med: 14.29 Max: 15.73
Current: 14.29
During the past 5 years, Sheel Biotech's highest ROC (Joel Greenblatt) % was 15.73%. The lowest was 6.77%. And the median was 14.29%.
NSE:SHEEL's ROC (Joel Greenblatt) % is ranked better than 54.72% of 1983
companies
in the Consumer Packaged Goods industry
Industry Median: 12.23
vs NSE:SHEEL: 14.29
Sheel Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sheel Biotech ROC (Joel Greenblatt) % Related Terms
Sheel Biotech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sheel Biotech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sheel Biotech ROC (Joel Greenblatt) % Chart
Sheel Biotech Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
ROC (Joel Greenblatt) %
6.77
9.33
15.73
15.42
14.29
Sheel Biotech Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
ROC (Joel Greenblatt) %
6.77
9.33
15.73
15.42
14.29
NSE:SHEEL vs ADM, BG, TSN: ROC (Joel Greenblatt) % Comparison
For the Farm Products subindustry, Sheel Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sheel Biotech ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Sheel Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sheel Biotech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is one times the annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 14.29% mean?
Sheel Biotech (NSE:SHEEL) has a ROC (Joel Greenblatt) % of 14.29% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sheel Biotech and its competitors. This is near median its historical median of 14.29. Over the past decade, Sheel Biotech's ROC (Joel Greenblatt) % has ranged from 6.77 to 15.73. According to the industry distribution chart, Sheel Biotech ranks #898 out of 1983 companies in the Consumer Packaged Goods industry, placing it in the top 45.3%.
Is Sheel Biotech's ROC (Joel Greenblatt) % too high?
Sheel Biotech's current ROC (Joel Greenblatt) % of 14.29% is near median its 10-year median of 14.29. Over the past 10 years, this metric has ranged from a low of 6.77 to a high of 15.73. The Consumer Packaged Goods industry median ROC (Joel Greenblatt) % is 12.23. Sheel Biotech's value of 14.29% is 16.8% above this industry median. Based on the distribution chart, Sheel Biotech ranks #898 out of 1983 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Sheel Biotech has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Sheel Biotech's ROC (Joel Greenblatt) % compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Sheel Biotech ranks #898 out of 1983 companies for ROC (Joel Greenblatt) %. This puts Sheel Biotech in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 12.23. Sheel Biotech's value of 14.29% is 16.8% above this benchmark. Historically, Sheel Biotech's own ROC (Joel Greenblatt) % has ranged from 6.77 to 15.73 over the past decade. While the company's 10-year median is 14.29 vs. the industry median of 12.23, Sheel Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 12.23, based on 1,983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sheel Biotech's current ROC (Joel Greenblatt) % of 14.29% is 16.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sheel Biotech and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 12.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sheel Biotech's current ROC (Joel Greenblatt) % is 14.29%, which is near median its own 10-year median of 14.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sheel Biotech stock overvalued right now?
Sheel Biotech (NSE:SHEEL) has a current ROC (Joel Greenblatt) % of 14.29%. The current ROC (Joel Greenblatt) % is 14.29%, which is near median its 10-year median of 14.29 and 16.8% above the Consumer Packaged Goods industry median of 12.23. Sheel Biotech's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sheel Biotech (NSE:SHEEL), the current ROC (Joel Greenblatt) % is 14.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sheel Biotech Ltd is engaged in the business of growing, developing, processing, and supplying a wide range of plants for field crops, fruits, vegetables, and ornamental plants through tissue culture and organic farming. It manufactures and maintain greenhouses, offer services to farmers and provide training through Farmer Producer Organizations (FPOs). The company also has a Research and Development lab with a capacity of production of 10 million* planting materials which is duly recognized by the Department of Biotechnology (DBT), Government of India.
19GF Score
Get the complete analysis for NSE:SHEEL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHEEL has been successfully added to your 
